Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Quiñones-Peña MA et al. | 2017 | bacterium, <i>Escherichia coli</i> (different strains) | static magnetic field | - |
Shang GM et al. | 2004 | intact cell/cell culture, <i>Taxus chinensis</i> var. <i>mairei</i> | static magnetic field, magnetic field, 50/60 Hz | - |
Wojcik-Piotrowicz K et al. | 2017 | intact cell/cell culture, U937 (human leukemic monocyte cell line) | magnetic field, static magnetic field, signals/pulses, 50/60 Hz, co-exposure | - |
Ben Mouhoub R et al. | 2018 | bacterium, <i>Salmonella enterica</i> subsp <i>enterica</i> serovar Hadar | static magnetic field | - |
Yuan LQ et al. | 2018 | intact cell/cell culture, nephroblastoma and neuroblastoma cell lines (G401, CHLA255, N2a), animal, nude mice, whole body | magnetic field, static magnetic field, 50/60 Hz | - |
Gilson RC et al. | 2018 | bacterium, <i>Plasmodium falciparum</i> HB3 strain | magnetic field, static magnetic field | - |
Amiri M et al. | 2018 | intact cell/cell culture, human glioblastoma cell line (U-87) | 50/60 Hz, static magnetic field, magnetic field, co-exposure, also other exposures without EMF | - |
Jalali A et al. | 2019 | intact cell/cell culture, A2780 (human ovarian carcinoma-sensitive to cisplatin) and A2780-CP (human ovarian carcinoma-resistant to cisplatin) | static magnetic field, also other exposures without EMF, co-exposure | - |
Lin SL et al. | 2019 | intact cell/cell culture, NK92-MI cells (human natural killer cell line) and K562 cells (human erythroleukemic cell line) | static magnetic field | - |
Kimsa-Dudek M et al. | 2019 | intact cell/cell culture, normal human dermal fibroblasts (NHDF) | static magnetic field, co-exposure | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.